The new oral factor-Xa inhibitor, rivaroxaban, appears to provide the same antioxidant support as injectable low molecular weight heparins (LMWHs).doi:10.1007/s11239-013-1019-4Caliskan, A.Yavuz, C.Karahan, O.Yazici, S.Guclu, O.Demirtas, S....
Only a small amount of factor Xa is needed to generate many molecules of thrombin. It has been hypothesized that this would be a better target for controlling thrombogenic events because it would require lower plasma levels of an inhibitor and should have a better therapeutic index for ...
Clinical Evaluation of Factor XIa Inhibitor Drugs 医学重症监护医学药理学 作者 Josephine Harrington,Jonathan P. Piccini,John H. Alexander,Christopher B. Granger,Manesh R. Patel 出处 期刊:Journal of the American College of Cardiology[Elsevier BV] ...
Apixaban, an oral direct factor Xa inhibitor: awaiting the verdict. Expert Opin. Investig. Drugs 17, 1937–1945 (2008). Article CAS PubMed Google Scholar Piccini, J. P., Patel, M. R., Mahaffey, K. W., Fox, K. A. & Califf, R. M. Rivaroxaban, an oral direct factor Xa ...
Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 2008 Dec; 17(12): 1937–45 Article PubMed CAS Google Scholar Bristol-Myers Squibb and Pfizer initiate new study in the apixaban phase 3 clinical trial program. June 10,2008 [press release; online...
作者:Yoon, Hyun Jung;Wu, Sangwook;Kundu, Sibsankar Thromboembolic disorders, arising from abnormal coagulation, pose a significant risk to human life in the modern world. The FDA has recently approved several anticoagulant drugs targeting factor Xa (FXa) to manage these disorders. However, these...
This retrospective, cohort study took place at a community hospital and included patients ≥18 years of age receiving 4F-PCC for major bleeding while on either warfarin or a factor-Xa inhibitor between January 2015 and December 2022. Patients received either fixed dose (treatment) or weight-based...
implicationsforthedesignofmoreefficientFXIamacrocyclicinhibitoranticoagulant drugs. Keywords: FactorXIa,macrocyclicinhibitors,moleculardynamicssimulation,MM-PBSA, inhibitionmechanism V 目录 目录 第1章绪论1 1.1FactorXIa结构功能简介1 1.2FXIa抑制剂简介2 1.3分子动力学模拟在生物体系中的应用和前景3 1.4论文的研究思路...
Low molecular weight, factor Xa-specific blood clotting inhibitors that are effective but do not cause unwanted side effects have been described, for example, in WO-A-95/29189. However, besides being an effective factor Xa-specific blood clotting inhibitor, it is desirable that such inhibitors ...
A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, Ki. Factor Xa determinations were made in 0.10 M sodium phosphate buffer, pH 7.5, containing 0.20 M NaCl, ...